Leading causes of castration-resistant prostate cancer

被引：0
|
作者：
Lu, Mingqian [1 ,2 ,3 ]
Lu, Hongda [4 ,5 ]
Kong, Qingzhi [4 ,5 ]
机构：
[1] Hubei Univ Chinese Med, Clin Med Coll, Wuhan 430061, Hubei Province, Peoples R China
[2] China Three Gorges Univ, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China
[3] Yichang Cent Peoples Hosp, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China
[4] Cent Hosp Wuhan, Dept Oncol, Wuhan 430014, Hubei Province, Peoples R China
[5] Canc Res Inst Wuhan, Wuhan 430014, Hubei Province, Peoples R China
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 04期
基金：
湖北省教育厅重点项目;
关键词：
androgen receptor; androgen receptor mutation; androgen receptor splicing; castration-resistant prostate cancer; neuroendocrine; progenitor cells; ANDROGEN RECEPTOR GENE; EPIDERMAL-GROWTH-FACTOR; ANTIANDROGEN WITHDRAWAL SYNDROME; TRANSGENIC MOUSE MODEL; TUMOR-CELL LINES; NEUROENDOCRINE DIFFERENTIATION; STEM-CELLS; SPLICE VARIANTS; FULL-LENGTH; CASODEX BICALUTAMIDE;
D O I：
10.1586/14737140.2015.1007957
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling. Even though androgen deprivation therapy shows its initial effectiveness on shrinking tumor size, it eventually fails to cure advanced PCa, which is determined by the occurrence of castration-resistance. In this review, we summarize the widely accepted mechanisms that account for castration-resistant PCa and discuss potential therapeutic targets.
引用
收藏
页码：425 / 432
页数：8
相关论文
共 50 条
  • [41] Sequencing of agents in castration-resistant prostate cancer
    Lorente, David
    Mateo, Joaquin
    Perez-Lopez, Raquel
    de Bono, Johann S.
    Attard, Gerhardt
    LANCET ONCOLOGY, 2015, 16 (06): : E279 - E292
  • [42] Biological Evolution of Castration-resistant Prostate Cancer
    Davies, Alastair
    Conteduca, Vincenza
    Zoubeidi, Amina
    Beltran, Himisha
    EUROPEAN UROLOGY FOCUS, 2019, 5 (02): : 147 - 154
  • [43] Management of Metastatic Castration-Resistant Prostate Cancer
    Srinivas, Sandy
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
  • [44] Rucaparib in castration-resistant, metastatic prostate cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2024, 55 (02) : 96 - 98
  • [45] Enzalutamide for Patients with castration-resistant Prostate Cancer
    Kessing, Richard
    AKTUELLE UROLOGIE, 2020, 51 (01)
  • [46] Aggressive Variants of Castration-Resistant Prostate Cancer
    Beltran, Himisha
    Tomlins, Scott
    Aparicio, Ana
    Arora, Vivek
    Rickman, David
    Ayala, Gustavo
    Huang, Jiaoti
    True, Lawrence
    Gleave, Martin E.
    Soule, Howard
    Logothetis, Christopher
    Rubin, Mark A.
    CLINICAL CANCER RESEARCH, 2014, 20 (11) : 2846 - 2850
  • [47] Castration-Resistant Prostate Cancer An Algorithmic Approach
    Stratton, Kelly
    Cookson, Michael
    UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) : 647 - 655
  • [48] ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
    Ha, Y-S
    Goodin, S.
    DiPaola, R. S.
    Kim, I. Y.
    DRUGS OF TODAY, 2013, 49 (01) : 7 - 13
  • [49] Chemotherapy options in castration-resistant prostate cancer
    Teply, Benjamin A.
    Hauke, Ralph J.
    INDIAN JOURNAL OF UROLOGY, 2016, 32 (04) : 262 - 270
  • [50] How to approach castration-resistant prostate cancer?
    Bavbek, Sevil
    MARMARA MEDICAL JOURNAL, 2015, 28 (04): : 24 - 34
12345